Yatin Dholakia
Overview
Explore the profile of Yatin Dholakia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dholakia Y, Govekar L, Mistry N
Indian J Tuberc
. 2024 Jul;
71 Suppl 1:S86-S90.
PMID: 39067962
Background: Drug-resistant tuberculosis (DRTB) is a significant public health threat particularly in high burden areas like Mumbai, India. Contacts of DRTB cases are highly vulnerable to infection and development of...
2.
Partap U, Sharma K, Marathe Y, Wang M, Shaikh S, Dcosta P, et al.
Curr Dev Nutr
. 2023 Aug;
7(8):101971.
PMID: 37560461
Background: There remains a need to identify low-cost interventions to improve coronavirus disease 2019 (COVID-19) outcomes. Vitamin D and zinc play a role in respiratory infections and could hold value...
3.
4.
Sharma K, Partap U, Mistry N, Marathe Y, Wang M, Shaikh S, et al.
BMJ Open
. 2022 Aug;
12(8):e061301.
PMID: 36038172
Introduction: Presently, there are few population-level strategies to address SARS-CoV-2 infection except preventive measures such as vaccination. Micronutrient deficiency, particularly vitamin D and zinc deficiency, has been associated with dysregulated...
5.
Mistry N, Hemler E, Dholakia Y, Bromage S, Shukla A, Dev P, et al.
BMJ Open
. 2020 Nov;
10(11):e039935.
PMID: 33184081
Introduction: Vitamin D status may be an important determinant of multidrug-resistant tuberculosis (MDR-TB) infection, progression to disease and treatment outcomes. Novel and potentially cost-effective therapies such as vitamin D supplementation...
6.
Shah S, Shah S, Rangan S, Rai S, Lobo E, Kamble S, et al.
Gates Open Res
. 2020 Jun;
4:32.
PMID: 32490358
Public-private interface agency (PPIA) intervention models in Patna (E. India) and Mumbai (W. India) for pulmonary drug-sensitive (DS) tuberculosis (TB) patients were evaluated over 2 years after maturity to examine...
7.
Lobo E, Shah S, Rangan S, Dholakia Y, Mistry N
Gates Open Res
. 2019 Sep;
2:9.
PMID: 29863175
Mumbai is witnessing a rising incidence of all forms of drug resistant tuberculosis (DR-TB). A population-based, retrospective study was conducted between April and July 2014, in 15 high TB burden...
8.
Bhattacharya Chakravarty A, Rangan S, Dholakia Y, Rai S, Kamble S, Raste T, et al.
PLoS One
. 2019 Jan;
14(1):e0209924.
PMID: 30653523
Introduction: The Indian Tuberculosis (TB) Programme currently faces the dual challenges of tackling increasing numbers of drug resistant (DR) TB cases and regulating practices of a pluralistic private sector catering...
9.
Mistry N, Lobo E, Shah S, Rangan S, Dholakia Y
J Epidemiol Glob Health
. 2017 Nov;
7(4):241-248.
PMID: 29110864
Background: Delays in accessing effective health care plays a pivotal role in increasing Tuberculosis (TB) transmission within the community. Patna, North India, with high levels of poverty and weak public...
10.
Dholakia Y, Mistry N
Indian J Tuberc
. 2017 Feb;
64(1):10-13.
PMID: 28166910
Congregate settings and correctional facilities have high risk of transmission of tuberculosis. They should have capacity to identify and diagnose cases early and initiate prompt treatment to prevent spread to...